| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA811: Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia (terminated appraisal) |
|
Medicine details |
|
| Medicine name | duvelisib (Copiktra®) |
| Formulation | 15 mg, 25 mg hard capsule |
| Reference number | 2918 |
| Indication | Treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies |
| Company | Secura Bio Inc. |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/05/2021 |
| NICE guidance | |